All In Biotech

Drug Trial Radar · NCT01121835

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study

A 24-week, Open, Multicenter, Comparative Study of 2 Strategies (Including Insulin Glargine Versus Premixed Insulin) for the Therapeutic Management of Patients With Type 2 Diabetes Failing Oral Agents

Last checked: Nov 20, 2026Latest source record: Apr 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 934 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

934

Actual

Start

Feb 2010

Primary completion

Mar 2012

Study completion Mar 2012

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 12, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To demonstrate the superiority of a strategy with insulin glargine in comparison with a strategy including the premixed insulin in term of percentage of patients reaching HbA1c (glycosylated hemoglobin) below 7% at the end of treatment and who do not experience documented symptomatic hypoglycemia (confirmed by a Plasma Glucose (PG) below 56 mg/dL (3.1 mmol/L)) over a 24-week treatment period, in Type 2 diabetes patients failing lifestyle management and oral agents. Secondary Objectives: To assess the effect of insulin glargine in comparison with premixed insulin on : * Evolution of HbA1c level during the treatment period Percentage of patients who reach the target of HbA1c \< 7 % and who do not experience documented symptomatic hypoglycemia confirmed by a Plasma Glucose (PG) below 70 mg/dL (3.9 mmol/L) * Percentage of patients who reach the target of HbA1c \< 6.5% and who do not experience documented symptomatic hypoglycemia confirmed by a PG below 56 mg/dL (3.1 mmol/L) \>Percentage of patients who reach the target of HbA1c \< 6.5% and who do not experience documented symptomatic hypoglycemia confirmed by a PG below 70 mg/dL (3.9 mmol/L) \>Evolution of Fasting Plasma Glucose Evolution of 7-point plasma glucose profiles * Evolution of weight * Hypoglycemia occurrence * Dose of insulins * Evolution of liver function * Overall safety

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • INSULIN GLARGINEDrug

    Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)

  • INSULIN GLULISINEDrug

    Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)

  • PREMIXED INSULINDrug

    Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico * 25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with Glycosylated Haemoglobin (HbA1c) <7% with no documented symptomatic hypoglycemia (confirmed by a Plasma Glucose (PG) ≤ 56 mg/dL [3.1 mmol/L]Time frame: From baseline (visit 2, week 0) to visit 14 (week 24)

Locations

96 sites in 16 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 040-004

    Sankt Stefan, Austria

  • Investigational Site Number 040-002

    Vienna, Austria

  • Investigational Site Number 040-001

    Vienna, Austria

  • Investigational Site Number 040-003

    Vienna, Austria

  • Investigational Site Number 076002

    Belém, Brazil

  • Investigational Site Number 076005

    Curitiba, Brazil

  • Investigational Site Number 076004

    Fortaleza, Brazil

  • Investigational Site Number 076001

    Porto Alegre, Brazil

  • Investigational Site Number 076003

    São Paulo, Brazil

  • Investigational Site Number 156004

    Beijing, China

  • Investigational Site Number 156005

    Beijing, China

  • Investigational Site Number 156006

    Beijing, China

  • Investigational Site Number 156011

    Chongqing, China

  • Investigational Site Number 156009

    Dalian, China

  • Investigational Site Number 156008

    Guangzhou, China

  • Investigational Site Number 156012

    Haikou, China

  • Investigational Site Number 156007

    Nanjing, China

  • Investigational Site Number 156001

    Shanghai, China

  • Investigational Site Number 156002

    Shanghai, China

  • Investigational Site Number 156003

    Shanghai, China

  • Investigational Site Number 156010

    Shenyang, China

  • Investigational Site Number 170001

    Bogotá, Colombia

  • Investigational Site Number 170002

    Bogotá, Colombia

  • Investigational Site Number 170003

    Bucaramanga, Colombia

  • Investigational Site Number 170005

    Manizales, Colombia

  • Investigational Site Number 170004

    Pereira, Colombia

  • Investigational Site Number 208-001

    Hvidovre, Denmark

  • Investigational Site Number 208-003

    København NV, Denmark

  • Investigational Site Number 208-002

    København S, Denmark

  • Investigational Site Number 300006

    Alexandroupoli, Greece

  • Investigational Site Number 300001

    Athens, Greece

  • Investigational Site Number 300002

    Athens, Greece

  • Investigational Site Number 300003

    Athens, Greece

  • Investigational Site Number 300004

    Athens, Greece

  • Investigational Site Number 300005

    Irakleio, Greece

  • Investigational Site Number 300011

    Maroussi, Athens, Greece

  • Investigational Site Number 300008

    Thessaloniki, Greece

  • Investigational Site Number 300010

    Thessaloniki, Greece

  • Investigational Site Number 300007

    Thessaloniki, Greece

  • Investigational Site Number 356008

    Bangalore, India

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.